S. Mark Berger's most recent trade in Genprex Inc was a trade of 4,500 Common Stock done at an average price of $0.2 . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Genprex Inc | Mark S. Berger | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.23 per share. | 30 Jun 2025 | 4,500 | 17,971 (0%) | 0% | 0.2 | 1,026 | Common Stock |
| Genprex Inc | Mark S. Berger | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.41 per share. | 18 Feb 2025 | 585 | 22,471 (0%) | 0% | 0.4 | 240 | Common Stock |
| Genprex Inc | Mark S. Berger | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Dec 2024 | 18,250 | 23,056 (0%) | 0% | 0 | Common Stock | |
| Genprex Inc | S. Mark Berger | Chief Medical Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.40 per share. | 18 Feb 2024 | 1,319 | 4,806 (0%) | 0% | 4.4 | 5,804 | Common Stock |
| Genprex Inc | Mark S. Berger | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Feb 2023 | 245,000 | 245,000 (0%) | 0% | 0 | Common Stock | |
| Genprex Inc | Mark S. Berger | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2022 | 98,750 | 98,750 | - | - | Stock Option (right to buy) |